JP Morgan Chase’s RVL Pharmaceuticals plc Ordinary Shares RVLP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-3
| Closed | – | – | 8081 |
|
|
2023
Q3 | $0 | Hold |
3
| – | – | ﹤0.01% | 7812 |
|
|
2023
Q2 | $2 | Hold |
3
| – | – | ﹤0.01% | 6856 |
|
|
2023
Q1 | $0 | Hold |
3
| – | – | ﹤0.01% | 7404 |
|
|
2022
Q4 | $0 | Hold |
3
| – | – | ﹤0.01% | 7187 |
|
|
2022
Q3 | $0 | Hold |
3
| – | – | ﹤0.01% | 7011 |
|
|
2022
Q2 | $0 | Hold |
3
| – | – | ﹤0.01% | 7048 |
|
|
2022
Q1 | $0 | Hold |
3
| – | – | ﹤0.01% | 7158 |
|
|
2021
Q4 | $0 | Sell |
3
-4,250
| -100% | -$6.9K | ﹤0.01% | 7090 |
|
|
2021
Q3 | $13K | Sell |
4,253
-33,353
| -89% | -$112K | ﹤0.01% | 6127 |
|
|
2021
Q2 | $113K | Buy |
37,606
+30,341
| +418% | +$92.9K | ﹤0.01% | 5500 |
|
|
2021
Q1 | $24K | Buy |
7,265
+1,643
| +29% | +$6.76K | ﹤0.01% | 5678 |
|
|
2020
Q4 | $23K | Buy |
5,622
+770
| +16% | +$4.44K | ﹤0.01% | 5280 |
|
|
2020
Q3 | $26K | Buy |
4,852
+822
| +20% | +$4.73K | ﹤0.01% | 5104 |
|
|
2020
Q2 | $27K | Buy |
4,030
+1,496
| +59% | +$7.32K | ﹤0.01% | 4983 |
|
|
2020
Q1 | $8K | Sell |
2,534
-89
| -3% | -$474 | ﹤0.01% | 5081 |
|
|
2019
Q4 | $18K | Buy |
2,623
+4
| +0.2% | +$21 | ﹤0.01% | 5332 |
|
|
2019
Q3 | $10K | Buy |
2,619
+425
| +19% | +$1.44K | ﹤0.01% | 5507 |
|
|
2019
Q2 | $8K | Sell |
2,194
-185
| -8% | -$615 | ﹤0.01% | 5596 |
|
|
2019
Q1 | $9K | Sell |
2,379
-557
| -19% | -$4.1K | ﹤0.01% | 5559 |
|
|
2018
Q4 | $22K | Buy |
+2,936
| New | +$23.5K | ﹤0.01% | 5307 |
|
Other funds holding RVLP
JP Morgan Chase's RVLP Position: Q4 2023 in Review
JP Morgan Chase sold out of RVL Pharmaceuticals plc Ordinary Shares (RVLP) in Q4 2023, closing a stake of 3 shares.
JP Morgan Chase first reported a position in RVLP in Q4 2018 and held it in 20 quarters. The position peaked at $113K in Q2 2021. 3 funds tracked by Wall St. Rank hold RVLP as of Q4 2023.
- JP Morgan Chase reported no remaining RVL Pharmaceuticals plc Ordinary Shares position as of Q4 2023 after selling out during the quarter.
- JP Morgan Chase sold 3 RVL Pharmaceuticals plc Ordinary Shares shares in Q4 2023.
- JP Morgan Chase first reported a position in RVL Pharmaceuticals plc Ordinary Shares in Q4 2018 and held it in 20 quarters.
- JP Morgan Chase's RVL Pharmaceuticals plc Ordinary Shares position peaked at $113K in Q2 2021.
- 3 funds tracked by Wall St. Rank held RVL Pharmaceuticals plc Ordinary Shares as of Q4 2023.
Based on JP Morgan Chase's 13F filing for Q4 2023, filed 12 Feb 2024.